Multimodality therapy of stage III adenocarcinoma of the breast.


The results of a pilot multimodality program (surgery + radiotherapy + chemotherapy) are reported in 34 women with advanced stage III and IV adenocarcinoma of the breast. The median relapse-free survival for all patients was 24 months, with 74% of the premenopausal patients and 37% of the postmenopausal alive at five years (P = 0.18). The relapse rate was significantly lower in premenopausal patients when compared to the postmenopausal subgroup. Estrogen receptor status was not predictive for relapse or survival.


Citations per Year

107 Citations

Semantic Scholar estimates that this publication has 107 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Bitran1983MultimodalityTO, title={Multimodality therapy of stage III adenocarcinoma of the breast.}, author={J D Bitran and R K Desser and D J Schifeling and Calli Shapiro and Mark F. Kozloff and Erwin Robin and Wendy M Recant and Andr{\'e} G. Michel and Hyman Rochman and Anthony A. Billings}, journal={Journal of surgical oncology}, year={1983}, volume={22 1}, pages={5-8} }